Catherine M T Sherwin

Summary

Affiliation: University of Utah
Country: USA

Publications

  1. ncbi request reprint Amikacin population pharmacokinetics among paediatric burn patients
    Catherine M T Sherwin
    Division of Clinical Pharmacology, Department of Paediatrics, University of Utah School of Medicine, Salt Lake City, Utah, United States Electronic address
    Burns 40:311-8. 2014
  2. doi request reprint Pharmacokinetic and pharmacodynamic optimisation of intravenous tobramycin dosing among children with cystic fibrosis
    Catherine M T Sherwin
    Department of Paediatrics, University of Utah School of Medicine, 295 Chipeta Way, Salt Lake City, UT, 84108, USA
    J Pharmacokinet Pharmacodyn 41:71-9. 2014
  3. pmc Optimal study design for pioglitazone in septic pediatric patients
    Catherine M T Sherwin
    Division of Clinical Pharmacology, Cincinnati Children s Hospital Medical Center, OH, USA
    J Pharmacokinet Pharmacodyn 38:433-47. 2011
  4. doi request reprint Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: II. cephalosporins and penicillins
    Jeffery T Zobell
    Pharmacy, Intermountain Primary Children s Medical Center, Salt Lake City, Utah 84113, USA
    Pediatr Pulmonol 48:107-22. 2013
  5. doi request reprint Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: VI. Executive summary
    Jeffery T Zobell
    Department of Pharmacy, Intermountain Primary Children s Medical Center, Salt Lake City, Utah, USA
    Pediatr Pulmonol 48:525-37. 2013
  6. ncbi request reprint Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: V. Aminoglycosides
    David C Young
    University of Utah College of Pharmacy, Salt Lake City, Utah Intermountain Cystic Fibrosis Adult Center, Salt Lake City, Utah
    Pediatr Pulmonol 48:1047-61. 2013
  7. ncbi request reprint Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: III. fluoroquinolones
    Chris Stockmann
    Division of Pediatric Infectious Disease, University of Utah, Salt Lake City, UT 84108, USA
    Pediatr Pulmonol 48:211-20. 2013
  8. doi request reprint Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: IV. colistimethate sodium
    David C Young
    University of Utah College of Pharmacy, Salt Lake City, Utah 84112, USA
    Pediatr Pulmonol 48:1-7. 2013
  9. ncbi request reprint Pharmacokinetics and pharmacodynamics of antibacterials, antifungals, and antivirals used most frequently in neonates and infants
    Jessica K Roberts
    Division of Clinical Pharmacology, Department of Pediatrics, University of Utah School of Medicine, University of Utah Health Sciences Center, 295 Chipeta Way, Salt Lake City, UT, 84108, USA
    Clin Pharmacokinet 53:581-610. 2014
  10. doi request reprint Population pharmacokinetics of intermittent vancomycin in children with cystic fibrosis
    Chris Stockmann
    Department of Pediatrics, University of Utah School of Medicine, Salt Lake City, Utah Department of Pharmacology and Toxicology, University of Utah College of Pharmacy, Salt Lake City, Utah
    Pharmacotherapy 33:1288-96. 2013

Collaborators

Detail Information

Publications26

  1. ncbi request reprint Amikacin population pharmacokinetics among paediatric burn patients
    Catherine M T Sherwin
    Division of Clinical Pharmacology, Department of Paediatrics, University of Utah School of Medicine, Salt Lake City, Utah, United States Electronic address
    Burns 40:311-8. 2014
    ..The objectives of this study were to (1) determine the pharmacokinetics of amikacin among children with severe burn and (2) identify influential covariates...
  2. doi request reprint Pharmacokinetic and pharmacodynamic optimisation of intravenous tobramycin dosing among children with cystic fibrosis
    Catherine M T Sherwin
    Department of Paediatrics, University of Utah School of Medicine, 295 Chipeta Way, Salt Lake City, UT, 84108, USA
    J Pharmacokinet Pharmacodyn 41:71-9. 2014
    ..In simulations, once daily dosing was the only regimen to achieve the pharmacodynamic target for all subjects with MICs <2 μg/mL. ..
  3. pmc Optimal study design for pioglitazone in septic pediatric patients
    Catherine M T Sherwin
    Division of Clinical Pharmacology, Cincinnati Children s Hospital Medical Center, OH, USA
    J Pharmacokinet Pharmacodyn 38:433-47. 2011
    ..The pharmacokinetics of pioglitazone were described adequately and simulated data estimates were comparable to literature values. The optimal design provided clinically attainable sample times and windows...
  4. doi request reprint Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: II. cephalosporins and penicillins
    Jeffery T Zobell
    Pharmacy, Intermountain Primary Children s Medical Center, Salt Lake City, Utah 84113, USA
    Pediatr Pulmonol 48:107-22. 2013
    ..The usefulness of high dose piperacillin (>600 mg/kg/day) may be limited due to treatment-related adverse effects. Further understanding of these adverse effects in CF patients is needed...
  5. doi request reprint Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: VI. Executive summary
    Jeffery T Zobell
    Department of Pharmacy, Intermountain Primary Children s Medical Center, Salt Lake City, Utah, USA
    Pediatr Pulmonol 48:525-37. 2013
    ....
  6. ncbi request reprint Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: V. Aminoglycosides
    David C Young
    University of Utah College of Pharmacy, Salt Lake City, Utah Intermountain Cystic Fibrosis Adult Center, Salt Lake City, Utah
    Pediatr Pulmonol 48:1047-61. 2013
    ..aeruginosa resistance with once-daily administration of tobramycin...
  7. ncbi request reprint Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: III. fluoroquinolones
    Chris Stockmann
    Division of Pediatric Infectious Disease, University of Utah, Salt Lake City, UT 84108, USA
    Pediatr Pulmonol 48:211-20. 2013
    ..Further study is needed to determine the tolerability and efficacy of levofloxacin in APE. At this time, the routine use of levofloxacin in the treatment of APE in pediatric and adult patients cannot be recommended...
  8. doi request reprint Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: IV. colistimethate sodium
    David C Young
    University of Utah College of Pharmacy, Salt Lake City, Utah 84112, USA
    Pediatr Pulmonol 48:1-7. 2013
    ..thrice-daily) and its impact on resistance and clinical efficacy. Further study is needed to determine the tolerability and efficacy of extended-interval dosing of CMS in the treatment of APE...
  9. ncbi request reprint Pharmacokinetics and pharmacodynamics of antibacterials, antifungals, and antivirals used most frequently in neonates and infants
    Jessica K Roberts
    Division of Clinical Pharmacology, Department of Pediatrics, University of Utah School of Medicine, University of Utah Health Sciences Center, 295 Chipeta Way, Salt Lake City, UT, 84108, USA
    Clin Pharmacokinet 53:581-610. 2014
    ..These studies will be invaluable in determining optimal neonatal dosing regimens that have the potential to improve clinical outcomes and decrease adverse effects associated with antimicrobial and antiviral treatments. ..
  10. doi request reprint Population pharmacokinetics of intermittent vancomycin in children with cystic fibrosis
    Chris Stockmann
    Department of Pediatrics, University of Utah School of Medicine, Salt Lake City, Utah Department of Pharmacology and Toxicology, University of Utah College of Pharmacy, Salt Lake City, Utah
    Pharmacotherapy 33:1288-96. 2013
    ..However, no studies have characterized the pharmacokinetic profile of vancomycin among pediatric cystic fibrosis patients...
  11. doi request reprint Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: I. aztreonam and carbapenems
    Jeffery T Zobell
    Pharmacy, Intermountain Primary Children s Medical Center, Salt Lake City, UT, USA
    Pediatr Pulmonol 47:1147-58. 2012
    ..The usefulness of imipenem-cilastatin may be limited due to the rapid development of resistance...
  12. ncbi request reprint Pharmacokinetics and pharmacodynamics of antifungals in children and their clinical implications
    Chris Stockmann
    Division of Clinical Pharmacology, Department of Paediatrics, University of Utah School of Medicine, 295 Chipeta Way, Salt Lake City, UT, 84108, USA
    Clin Pharmacokinet 53:429-54. 2014
    ..Further study is needed to translate these findings into optimal dosing regimens for children and to understand how these agents interact when multiple antifungal agents are used in combination...
  13. doi request reprint Characteristics and publication patterns of obstetric studies registered in ClinicalTrials.gov
    Chris Stockmann
    Department of Pediatrics, University of Utah School of Medicine, Salt Lake City, UT, USA Department of Pharmacology Toxicology, University of Utah College of Pharmacy, Salt Lake City, UT, USA
    J Clin Pharmacol 54:432-7. 2014
    ..The sources of this trend should be closely investigated. ..
  14. doi request reprint Evolution of interventional vancomycin trials in light of new antibiotic development in the USA, 1999-2012
    Tian Yu
    Division of Clinical Pharmacology, Department of Pediatrics, University of Utah, Salt Lake City, Utah, USA
    Int J Antimicrob Agents 43:215-22. 2014
    ..Further studies are warranted to determine how these agents can best be incorporated within clinical practice. ..
  15. ncbi request reprint Preliminary assessment of zolpidem pharmacokinetics in pediatric burn patients
    Chris Stockmann
    Division of Clinical Pharmacology, Department of Pediatrics, University of Utah School of Medicine, Salt Lake City James L Winkle College of Pharmacy, University of Cincinnati The Shriners Hospitals for Children and Department of Surgery, University of Cincinnati, OH
    Ther Drug Monit 36:295-301. 2014
    ..Severely burned patients frequently experience sleep fragmentation and insomnia. This study evaluated the population pharmacokinetics of the sleep-enhancing agent zolpidem among burned children...
  16. ncbi request reprint Use of methylxanthine therapies for the treatment and prevention of apnea of prematurity
    Katherine Schoen
    Division of Clinical Pharmacology, Department of Paediatrics, University of Utah School of Medicine, 295 Chipeta Way, Salt Lake City, UT, 84108, USA
    Paediatr Drugs 16:169-77. 2014
    ....
  17. doi request reprint Maternal magnesium sulphate exposure predicts neonatal magnesium blood concentrations
    Catherine M T Sherwin
    Division of Clinical Pharmacology, Department of Pediatrics, University of Utah School of Medicine, Salt Lake City, Utah, USA
    Basic Clin Pharmacol Toxicol 114:318-22. 2014
    ..05 for all). Maternal magnesium concentrations correlate with neonatal exposure. This finding suggests that maternal monitoring deserves further evaluation as a marker of foetal toxicity...
  18. doi request reprint Considerations in the pharmacologic treatment and prevention of neonatal sepsis
    Chris Stockmann
    Division of Clinical Pharmacology, Department of Paediatrics, University of Utah School of Medicine, Salt Lake City, USA
    Paediatr Drugs 16:67-81. 2014
    ..Additionally, several large multicenter studies are currently investigating the safety and efficacy of oral lactoferrin as an immunoprophylactic agent for the prevention of neonatal sepsis. ..
  19. doi request reprint Development of levofloxacin inhalation solution to treat Pseudomonas aeruginosa in patients with cystic fibrosis
    Chris Stockmann
    University of Utah Health Sciences Center, 295 Chipeta Way, Clinical Pharmacology, Salt Lake City, UT 84108, USA
    Ther Adv Respir Dis 8:13-21. 2014
    ....
  20. doi request reprint Population pharmacokinetic and pharmacodynamic modeling of high-dose intermittent ticarcillin-clavulanate administration in pediatric cystic fibrosis patients
    Jeffery T Zobell
    Pharmacy, Intermountain Primary Children s Medical Center, Salt Lake City, Utah, USA
    Clin Ther 33:1844-50. 2011
    ..This dosing strategy is higher than the Food and Drug Administration (FDA)-approved package labeling. We evaluated the microbiologic efficacy of this dosing regimen...
  21. pmc Characteristics of antimicrobial studies registered in the USA through ClinicalTrials.Gov
    Chris Stockmann
    Department of Paediatrics, University of Utah School of Medicine, Salt Lake City, UT, USA
    Int J Antimicrob Agents 42:161-6. 2013
    ..Leveraging the application of these data to guide the careful selection of antimicrobial agents will be essential to preserve their utility for years to come. ..
  22. doi request reprint Fundamentals of population pharmacokinetic modelling: validation methods
    Catherine M T Sherwin
    Division of Clinical Pharmacology Clinical Trials Office, Department of Pediatrics, University of Utah School of Medicine, Salt Lake City, UT, USA
    Clin Pharmacokinet 51:573-90. 2012
    ..There is a need to further standardize and establish the best approaches in modelling so that any model created can be systematically evaluated and the results relied upon...
  23. doi request reprint Variability of histamine pharmacodynamic response in children with allergic rhinitis
    Bridgette L Jones
    Department of Paediatrics, University of Missouri, Kansas City, MO 64108, USA
    J Clin Pharmacol 53:731-7. 2013
    ..86) than the entire cohort (r(2)  = 0.64). These data demonstrate a hyper-responsive histamine phenotype via HILD. This finding is important to future pharmacologic studies of antihistamines. ..
  24. ncbi request reprint Utilization of optimal study design for maternal and fetal sheep propofol pharmacokinetics study: a preliminary study
    Catherine M T Sherwin
    Clinical Anesthesia and Pediatrics, Cincinnati Children s Hospital Medical Center, 3333 Burnet Avenue, MLC 2001, Cincinnati, OH 45229, USA
    Curr Clin Pharmacol 9:64-9. 2014
    ..Initial evaluation of samples collected from three sheep using the optimal design strategy confirmed the performance of the design in obtaining effective PK parameter estimates...
  25. pmc Development of population PK model with enterohepatic circulation for mycophenolic acid in patients with childhood-onset systemic lupus erythematosus
    Catherine M T Sherwin
    Division of Clinical Pharmacology, Cincinnati Children s Hospital Medical Center, Cincinnati, Ohio 45229 3039, USA
    Br J Clin Pharmacol 73:727-40. 2012
    ..This study aimed to develop a population pharmacokinetic (PK) enterohepatic recycling model for MPA in patients with childhood-onset systemic lupus erythematosus (cSLE)...
  26. pmc Population pharmacokinetic modeling of risperidone and 9-hydroxyrisperidone to estimate CYP2D6 subpopulations in children and adolescents
    Catherine M T Sherwin
    Division of Clinical Pharmacology, Cincinnati Children s Hospital Medical Center, 3333 Burnet Avenue, MLC 6018, Cincinnati, OH 45229 3039, USA
    Ther Drug Monit 34:535-44. 2012
    ..The study aims were to characterize risperidone and (±)-9-hydroxyrisperidone pharmacokinetic (PK) variability in children and adolescents and to evaluate covariate effects on PK parameters...